Perspectives
Patients with diabetes show poor adherence to heart disease drugs
March 1, 2020Adherence to heart disease therapies dropped by half within one year
This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.
- Glucagon like peptide-1 agonists (GLP-1)
- Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
- Dipeptidyl peptidase-4 inhibitors (DPP-4i)
All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90% in their clinical trials.)
Related news
Perspectives
April 19, 2024
AMCP 2024: Behind the Research with Prerak Parikh
Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars
Perspectives
April 19, 2024
LISTEN NOW: Live at AMCP Annual 2024 – Digging into managed care pharmacy insights | Pharmacy Friends podcast
In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)'s 2024 Annual Meeting in New Orleans
Perspectives
April 17, 2024
AMCP 2024: Behind the research with YuQian Liu
Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier